Introduction
The past 50 years have seen significant therapeutic advances in the treatment of multiple myeloma. However, important observations about the disease were made over 150 years ago, in particular, in the case of a 45-year-old London tradesman, Thomas Alexander McBean. 1 One day while walking, he stumbled, fell, and was seized with a severe pain in his chest. Over the course of 2 years, he was treated for recurrent severe pain with a variety of treatments: a strengthening plaster to the chest, removal of a pound of blood, maintenance therapy consisting of the application of leeches, and later, cupping, and steel and quinine. Remission from this last treatment, as was the case with all the others, did not last long. McBean's consulting physician, William Macintyre, MD, recognized the features of Bence Jones proteinuria, and when McBean's pain recurred, Dr Macintyre consulted Henry Bence Jones, MD, the leading chemical pathologist of London of the day. Bence Jones erroneously concluded that the protein that precipitated when McBean's urine sample was heated and cooled was a hydrated deuteroxide of albumen. However, he did make the statement that any patient with mollities ossium (softening of the bone) should be examined for this peculiar protein. Bence Jones prescribed alum in order to reduce the excretion of animal matter in McBean's urine. This was of no avail and on January 1, 1846, McBean died of 'atrophy from albuminuria.' At autopsy, his bones cut like butter and in a drawing the marrow appeared to contain malignant plasma cells. However, McBean was not the first case on record of multiple myeloma. In 1844, Sarah Newbury was described by her physician, Samuel Solly, MD, as having multiple fractures. He made an interesting statement about the role of blood vessels in the disease, 'in which the earthy matter of the bone marrow is absorbed and thrown out by the kidneys in the urine'.
The topic of proteinuria lay dormant for many years until 1922, when Stanhope Bayne-Jones, MD, a professor at Johns Hopkins University, injected a number of Bence Jones proteins into rabbits and concluded that there were two or possibly three types of Bence Jones protein. 2 
To treat or not to treat
Based on the number of historic treatments for multiple myeloma administered to McBeanFDover's powder, camphor julep, tincture of camphor, and acetate of ammonia, in addition to the ones mentioned aboveFit is clear that many therapeutic modalities have been used over the years. Physicians are anxious to do the best they possibly can for their patients and as a result can be deluded easily by seeing and remembering those patients who respond nicely and forgetting those who are no longer among us. Several examples underscore this issue. One is a subset of myeloma called smoldering multiple myeloma. These patients have a large M protein in the serum and/or an increase in plasma cells above 10% in the bone marrow, which fulfills the minimal criteria for the diagnosis of myeloma. However, these patients have no anemia; their renal function is normal; their calcium level is within normal limits; they have no lytic bone lesions; and the plasma cell labeling index (proliferative rate of the plasma cell growth) is very low. In other words, these patients biologically have a monoclonal gammopathy of undetermined significance and should be recognized as such. They should not be treated because they may remain stable for many years. It is important in evaluating a patient with multiple myeloma that doctors adhere to the recommendations of Hippocrates, who wrote 2500 years ago that it was necessary to study all that one can see, feel, and hear, and everything that one can recognize before deciding how to treat a patient.
Another example of therapy has to do with a paper written in 1947 by Nils Alwall from the University of Lund in Sweden, who advocated the use of urethane followed by stilbamidine. 6, 7 One of his patients had a marked decrease in globulin, a decrease in plasma cells in the bone marrow, and an increase in hemoglobin after urethane treatment. For the next 20 years, urethane was the treatment of choice for multiple myeloma based on the response of one patient.
Finally in 1966, the Eastern Solid Tumor Group reported a prospective study of patients with multiple myeloma who were randomized to urethane or a placebo. 8 No difference in survival was demonstrated. In this study, the placebo was cola syrup. The patients who received placebo did not complain of nausea or vomiting; they had no leukopenia or thrombocytopenia, all of which are side effects of urethane. This demonstrates that all therapies and all therapeutic modalities must be looked at in a prospective, randomized manner in order to decide whether the new treatment is better than the old.
More recent treatments
An important advance was made in 1958 by Blokhin et al 9 from Russia and 4 years later by Bergsagel and colleagues 10 at MD Anderson Cancer Center, demonstrating the benefit of melphalan in the treatment of multiple myeloma. Today, melphalan and prednisone are a reasonable approach for the patient who is not a transplant candidate. Melphalan and prednisone produce an objective response in about 50-60% of patients. The dose of melphalan should be altered (based on blood counts at midcycle) in order to produce some cytopenia. Certain patients do not absorb melphalan adequately and the dose needs to be increased to obtain a pharmacologic effect.
As melphalan and prednisone produce an objective response in only a little more than half the patients, many investigators developed a wide variety of combinations of alkylating agents. A meta-analysis by the Oxford Myeloma Trialists summarizes 35 years of clinical investigation in the treatment of multiple myeloma, including 20 trials and 4930 patients. The response rate of the various combinations of chemotherapy was superior (Po0.00001) to melphalan and prednisone, but there was no difference in overall survival. Furthermore, there was no subset of myeloma patients who responded better with a combination than with single agents. It was previously claimed that patients with unfavorable prognostic features did better with a combination of alkylating agents, but that could not be confirmed in this study. A downside of using alkylating agents in multiple myeloma is the risk of development of myelodysplasia or acute leukemia. 11 In general, if a patient is less than 70 years of age, an autologous stem cell transplant should be considered.
The Medical Research Council of Great Britain recently published a prospective study of 401 patients who were randomized to receive a combination of Adriamycin, BCNU, cyclophosphamide, and melphalan or an autologous stem cell transplant with melphalan 200 mg/m 2 as the induction therapy. Survival for the chemotherapy-treated patients was 42 months and for the transplant patients 54 months. 12 Several studies have been conducted to determine if tandem transplants are more effective than a single one. A French group reported that the 7-year event-free and overall survival was superior in patients who received a double transplant. 13 However, their study reported a difference favoring tandem transplant. Nonmyeloablative allogeneic transplant, used in acute leukemia, is in its infancy for multiple myeloma. The ideal preparative regimen and the best post-transplant immunosuppressive regimen have not yet been developed for multiple myeloma. In addition, transplant-related mortality runs 15-20% in most studies, and the chronic graft-versus-host symptoms are very troublesome to the patient (Kroger N et al. Blood 2002; 100: 620a; abstract). 14, 15 Three novel agents have been introduced in the last several years for the treatment of multiple myeloma. One is thalidomide, first reported by the University of Arkansas. 16 In multiple studies, approximately one-third of patients with refractory disease responded (Grosbois B et al. Blood 2001; 98: 163a; abstract). 16, 17 A variety of agents have been used in combination with thalidomide for recurrent or refractory multiple myeloma (Tricot G et al. Blood 2001; 98: 850a; abstract), 18, 19 and one study of thalidomide with dexamethasone and clarithromycin reported 100% objective response. 20 A study of newly diagnosed multiple myeloma patients reported an 88.9% response rate when patients were given melphalan, prednisone, and thalidomide ( While these results may be overly optimistic, combination therapy with these novel agents, nonetheless, appears to be a worthwhile approach.
CC-5013 (lenalidomide; Revlimid), an analogue of thalidomide, is another new agent being investigated. In a phase I study, a response rate of 29% was observed, and some responses occurred in patients who had become refractory to thalidomide. 21 An ongoing study with a planned randomization of over 300 patients is comparing dexamethasone and Revlimid with dexamethasone and placebo. Data are still to be released.
Another new agent, PS-341 (bortezomib; Velcade), a proteosome inhibitor, elicited a 35% objective response rate in 193 relapsed or refractory patients. 22 Many of these patients had had an autologous stem cell transplant and a variety of other agents after relapse before receiving bortezomib. Nevertheless, a number of these responses were complete. Furthermore, the duration of response was 12 months. An ongoing randomized study of bortezomib vs dexamethasone was stopped early because of the superiority of bortezomib ( 102: 236a; abstract), which caused some concern because both agents produce a sensory-motor peripheral neuropathy, one of the major problems with long-term thalidomide treatment. The investigators reported an objective response of 63% in 56 relapsed and refractory patients and found no undue toxicity from the peripheral neuropathy.
Conclusions
The stories of two physicians, Alexander Fleming and Ernest Duchesne, can be illustrative not only in multiple myeloma but in any field of investigative endeavor. Alexander Fleming accidentally discovered penicillin in 1928 when a careless technician left Petri dishes uncovered in the laboratory. Fleming returned from holiday to find that the experiment had been ruined. Most investigators would have castigated the technician and started the experiment anew, but Dr Fleming examined the specimens and saw that there were clear rings surrounding the bacteria. He investigated why this might be, and the rest is history.
More than 30 years prior to Fleming's discovery, Ernest Duchesne graduated from the French Military Medical School in Paris and went to the University of Lyons for postgraduate training. Upon the suggestion of his chief that he study the effect of fungi upon bacteria, Duchesne cultured the mold Penicillium glaucum, and then, working with guinea-pigs and a variety of bacteria, he observed that the supernate from the cultured mold innoculated into animals could attenuate in notable proportions the virulence of the bacteria. Duchesne's thesis did not attract attention and was sent to the Curie Institute in Paris. Duchesne continued his military activities, developed tuberculosis 15 years later, and died. In a lecture delivered in 1947 in Lyons, Fleming credited Duchesne's contribution, saying that his own discovery of the antibacterial effect of fungi was by chance, whereas Duchesne's observations were made through methodic investigations. The importance of paying attention to data, whether by chance or planned, old or new, is clear from the examples of Fleming and Duchesne.
Five decades of therapy for multiple myeloma RA Kyle Despite many advances in the field of multiple myeloma, there are still important challenges ahead. Better preparative regimens are needed. The major cause of relapse following autologous stem cell transplant is the failure to destroy the tumor. We also need to be able to remove the tumor cells effectively and, more importantly, their precursors from the reinfused stem cells. We need to develop safer, allogeneic transplants for multiple myeloma. And despite the variety of new drugs, we still need new, improved agents for the treatment of this disease. This is a very exciting time in the field of multiple myeloma, and we are going to see many advances in the years ahead.
